The PRODIGE 7 randomized trial has 4 design flaws and 4 pharmacologic flaws and cannot be used to discredit other HIPEC regimens

類似資料

• Ovarian cancer with peritoneal metastases has many treatment options and HIPEC is here to stay
  著者:: Sugarbaker, Paul H., 等
  出版事項: (2021)
• Adjuvant HIPEC for gastric cancer
  著者:: Sugarbaker, Paul H., 等
  出版事項: (2021)
• Single institution best recommendation is HIPEC with cisplatin and docetaxel
  著者:: Sugarbaker, Paul H., 等
  出版事項: (2021)
• Peritoneal progression after pancreaticoduodenectomy is a devastating surgical treatment failure: HIPEC gemcitabine is an option
  著者:: Sugarbaker, Paul H., 等
  出版事項: (2021)
• Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: lessons learned from PRODIGE 7
  著者:: Cashin, Peter, 等
  出版事項: (2021)